Seagen's high­est sell­ing drug snags a la­bel ex­pan­sion for pe­di­atric can­cer pa­tients

Seagen’s top-sell­ing drug just scored an­oth­er in­di­ca­tion, a few weeks af­ter ex­ecs boost­ed their full-year sales ex­pec­ta­tions.

The com­pa­ny’s Take­da-part­nered an­ti­body drug con­ju­gate Ad­cetris is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER